Biotech

All Articles

Actinogen's cortisol blocker fails stage 2 anxiety study

.Actinogen Medical's cortisol blocker has missed out on the major endpoint of a period 2 research in...

Bivictrix decides going personal only means to take ADC into medical clinic

.Antibody-drug conjugates (ADCs) have actually gone to the center of lots of a billion-dollar biobuc...

TPG leadings up funds to $580M for assets throughout life sciences

.Property supervisor TPG, which has actually supported biotechs like Sionna Therapeutics as well as ...

Merck ceases stage 3 TIGIT test in bronchi cancer for futility

.Merck &amp Co.'s TIGIT system has actually endured one more misfortune. Months after shuttering a s...

After a difficult year, Exscientia folds up right into Recursion

.After a year specified through pipeline hairstyles, the variation of its own CEO and unemployments,...

Cullinan, after $25M deal, return bispecific to Port

.Cullinan Rehab was excited good enough with Port BioMed's bispecific immune system activator that i...

A deeper examine Strong Biotech's Intense 15

.Within this full week's episode of "The Leading Line," our experts're diving right into Brutal Biot...

Lilly experiences stage 2 failure of tau-targeting med

.The confetti is actually still flying from Eli Lilly's party celebrating the approval of Alzheimer'...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of substantial management hirings, firings a...

Lykos will definitely talk to FDA to reevaluate its selection following turndown of MDMA therapy for post-traumatic stress disorder

.Complying with a bad revealing for Lykos Therapeutics' MDMA applicant for trauma at a recent FDA ad...